NeuroActiva Revenue and Competitors

NeuroActiva, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of new drugs to treat Alzheimer’s disease. There are more than 5 million people in the US and 43 million people worldwide have Alzheimer’s disease. The growth in the prevalence of Alzheimer’s disease over the next few decades is anticipated to result in great pressure on the social and health-care systems of developed and developing economies alike. Alzheimer is the only disease that can not be prevented, stopped or cured. The current unmet needs represent a huge opportunity for pharmaceutical companies, which are developing targeted novel therapies. The recent failure of Aβ-targeted therapeutics in Phase III clinical trials suggests that it is timely and prudent to consider alternative drug discovery strategies for Alzheimer's disease. Traneurocin (NA-831): NeuroActiva has developed a new platform of products are designed to protect and repair damage caused by disease, trauma or old age, as well as to regenerate new neurons to activate the neurotransmission to restore the cognitive and mental capacity of Alzheimer patients. Our first drug candidate in clinical development is NA-831 (Traneurocin) which has excellent safety profile with no adverse effects observed. The drug is administered orally in a dosage form for the treatment of Alzheimer's disease. NA-831 is in Phase 2 clinical trial in 2018. Vineurocin (NA-704): Our second drug candidate, Vineurocin (NA-704) that can regulate cell growth and development, especially in nerve cells, as well as cellular DNA synthesis. NA-704 exhibits neuroprotection and neurogenesis, which has been demonstrated as a strong candidate for treatment of Alzheimer’s disease and other neurological disorders. NA-704 is administered intravenously once a week, per prescription of a qualified physician. NA-704 is in Phase 2 clinical trial in 2018. MICROS Controlled Release Infusion System: Besides biopharmaceutical, NeuroActiva has developed an advanced intravenous drug delivery, known as the MICROS Infusion System, which can be pre-filled with NA-704 to control release an accurate amount of the dosage to patient in hospital as well as in homecare setting. The MICROS infusion system has been approved for marketing in the USA. NeuroActiva’s proprietary technologies have resulted in products that have increased efficacy and/or reduced side effects relative to their precursors and to competing products. NeuroActiva applies a commercially driven approach to R&D activities, while seeking to partner with other pharmaceutical companies to share risk and reward in marketing the Alzheimer drugs in the United States and around the world.